Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants

PHASE2CompletedINTERVENTIONAL
Enrollment

1,320

Participants

Timeline

Start Date

February 9, 2011

Primary Completion Date

March 18, 2013

Study Completion Date

March 18, 2013

Conditions
Infections, Streptococcal
Interventions
BIOLOGICAL

Pneumococcal vaccine GSK 2189242A (LD formulation 1)

Intramuscular injection

BIOLOGICAL

Pneumococcal vaccine GSK 2189242A (HD formulation 2)

Intramuscular injection

BIOLOGICAL

Synflorix™

Intramuscular injection

BIOLOGICAL

Prevnar13™

Intramuscular injection

BIOLOGICAL

Tritanrix™-HepB/Hib

Intramuscular injection

BIOLOGICAL

Polio Sabin™

Orally

BIOLOGICAL

M-Vac™

Intramuscular injection

BIOLOGICAL

Stamaril™

Intramuscular injection

Trial Locations (1)

Unknown

GSK Investigational Site, Banjul

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

PATH

OTHER

collaborator

Department of State for Health and Social Welfare, The Gambia

OTHER_GOV

collaborator

Medical Research Council Unit, The Gambia

OTHER

collaborator

London School of Hygiene and Tropical Medicine

OTHER

lead

GlaxoSmithKline

INDUSTRY

NCT01262872 - Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants | Biotech Hunter | Biotech Hunter